0001209191-21-050934.txt : 20210811
0001209191-21-050934.hdr.sgml : 20210811
20210811171415
ACCESSION NUMBER: 0001209191-21-050934
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20210809
FILED AS OF DATE: 20210811
DATE AS OF CHANGE: 20210811
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Levin Andrew David
CENTRAL INDEX KEY: 0001867539
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-40708
FILM NUMBER: 211164558
MAIL ADDRESS:
STREET 1: C/O ELIEM THERAPEUTICS, INC.
STREET 2: 23515 NE NOVELTY HILL RD, STE B221 #125
CITY: REDMOND
STATE: WA
ZIP: 98053
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Eliem Therapeutics, Inc.
CENTRAL INDEX KEY: 0001768446
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 832273741
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 23515 NE NOVELTY HILL RD., SUITE B221 #1
CITY: REDMOND
STATE: WA
ZIP: 98077
BUSINESS PHONE: 16502240857
MAIL ADDRESS:
STREET 1: 23515 NE NOVELTY HILL RD., SUITE B221 #1
CITY: REDMOND
STATE: WA
ZIP: 98077
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2021-08-09
0
0001768446
Eliem Therapeutics, Inc.
ELYM
0001867539
Levin Andrew David
C/O ELIEM THERAPEUTICS, INC.
23515 NE NOVELTY HILL RD, STE. B221 #125
REDMOND
WA
98053
1
0
0
0
Stock Option (Right to Buy)
12.50
2021-08-09
4
A
0
20000
0.00
A
2031-08-08
Common Stock
20000
20000
D
For so long as the Reporting Person continuously provides services to the Issuer, this option will vest with respect to the shares as follows: 1/36th of the shares will vest on each monthly anniversary of August 1, 2021.
Under the Reporting Person's arrangement with RA Capital Management, L.P. (the "Adviser"), the Reporting Person holds the stock option for the benefit of the RA Capital Healthcare Fund, L.P. (the "Fund"), RA Capital Nexus Fund, L.P. (the "Nexus Fund"), RA Capital Nexus Fund II, L.P. (the "Nexus Fund II"), and a separately managed account (the "Account"). The Reporting Person is obligated to turn over to the Adviser any net cash or stock received upon exercise of the stock option, which will offset advisory fees owed by the Fund, the Nexus Fund, the Nexus Fund II, and the Account to the Adviser. The Reporting Person therefore disclaims beneficial ownership of the stock option and underlying Common Stock.
/s/ Alan Hambelton, Attorney-in-Fact
2021-08-11